Please use this identifier to cite or link to this item:
http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/5384
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Bezrukov, L.O. | en |
dc.contributor.author | Koloskova, O.K. | en |
dc.contributor.author | Marusyk, U.I. | en |
dc.contributor.author | Belashova, O.V. | en |
dc.date.accessioned | 2013-01-25T20:55:32Z | |
dc.date.available | 2013-01-25T20:55:32Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 616.248-059.3-085 | |
dc.identifier.uri | http://dspace.bsmu.edu.ua:8080/xmlui/handle/123456789/5384 | |
dc.description.abstract | The effect of Nucleinat included in the basic therapy of bronchial asthma (BA) has been analyzed by means of double-blind, placebo-controlled method in 98 school age children. Two clinical groups were formed with the help of the table accidental numbers. The application of the Nucleinat in complex anti-inflammatory therapy of the BA was accompanied by decrease of bronchial hyperresponsiveness due to the possible reduction of the inflammatory process activity in the airways. The use of Nucleinat in the basic therapy of the school-age children significantly reduced the risk of moderate bronchial responsiveness: DAR – 28,5%, DRR – 54,8%, MNT – 1,8 (95% CІ 0,1-7,1). | ru_RU |
dc.language.iso | other | ru_RU |
dc.relation.ispartofseries | Сборник научных трудов SWorld. Материалы международной научно-практической конференции «Современные проблемы и пути их решения в науке, транспорте, производстве и образовании'2012».;Выпуск 4. Том 412 | |
dc.subject | children | ru_RU |
dc.subject | bronchial asthma | ru_RU |
dc.subject | bronchial hyperresponsiveness | ru_RU |
dc.subject | Nucleinat. | ru_RU |
dc.title | The modern possibilities of increasing the efficiency of basic anti-inflammation therapy of school-age children’s bronchial asthma | ru_RU |
dc.type | Article | ru_RU |
Appears in Collections: | Статті. Кафедра педіатрії та дитячих інфекційних хвороб |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.